丹纳赫公司(DHR)今日盘前股价大跌5.38%,引发了市场的广泛关注。此前,该公司公布的2024年第四季度财报显示,受生物技术需求疲软拖累,当季利润不及预期。
具体来看,丹纳赫上季度实现调整后每股收益2.14美元,低于分析师预期的2.16美元。在生命科学和诊断业务等关键领域,该公司销售额虽有所增长,但仍无法满足市场预期。公司解释称,小型生物技术客户以及制药公司在药物开发方面的支出仍较为谨慎,导致相关产品和服务需求疲软。
此外,丹纳赫预计2025年第一季度调整后核心营收同比将下降低个位数,加剧了投资者对公司未来增长前景的担忧。目前看来,疫情后生物科技行业复苏乏力,对丹纳赫业绩造成了一定冲击,这也是该股今日大跌的主要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.